Table 5A Progression-free survival in patients with SD as best response

Patient number	Tumour type	Dose level (mg m ⁻²) (day 1/2/3)	Progression-free survival (days)
01–002	Prostate	1.2	112
01–006	Cholangiocarcinoma	2.5	89
01–010	Colorectal	5	112
01–012	Non-small cell lung	10	52^a
01–017	Pancreas	40	57^a
01–022	Adenocarcinoma	66.8	63^a
03–029	Prostate	88	119
03–031	Endometrial	40/66.8/66.8	77^a
03–036	Hepatocellular	40/66.8/66.8	336
03–037	Prostate	40/66.8/66.8	121^a
03–043	Hepatocellular	40/66.8/66.8	133
03–044	Hepatocellular	40/66.8/66.8	277^a

Quick links

Search